Filtered By:
Therapy: Gene Therapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 490 results found since Jan 2013.
Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems
Abstract: The evolution of synthetic RNAi faces the paradox of interfering with the human biological environment. Due to the fact that all cell physiological processes can be target candidates, silencing a precise biological pathway could be challenging if target selectivity is not properly addressed. Molecular biology has provided scientific tools to suppress some of the most critical issues in gene therapy, while setting the standards for siRNA clinical application. However, the protein down-regulation through the mRNA silencing is intimately related to the sequence-specific siRNA ability to interact accurately with the ...
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - December 11, 2013 Category: Nanotechnology Authors: M. Videira, A. Arranja, D. Rafael, R. Gaspar Tags: Cell Biology and Genetics, Amino Acids, Nucleic Acids, siRNA Therapy, Basic Science vs. Engineering Source Type: research
Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells
& H Uludağ
Source: Cancer Gene Therapy - March 1, 2013 Category: Cancer & Oncology Authors: H M AliabadiP MahdipoorH Uludağ Tags: lipophilic polymers Mcl-1 multidrug resistance P-glycoprotein siRNA delivery Source Type: research
Preparation of siRNA encapsulated nanoliposomes suitable for siRNA delivery by simply discontinuous mixing.
In this study, we prepared nanoliposomes encapsulating siRNA by simply discontinuous mixing of lipids in ethanol/ether/water mixture and acidic siRNA solution without use of special equipment. The simple mixing siRNA/liposomal particles (siRNA/SMLs) prepared using ethanol/ether/water (3:1:1) mixture showed 120.4 ± 20.2 nm particle size, 0.174 ± 0.033 polydispersity and 86.5 ± 2.76% siRNA encapsulation rate. In addition, the SMLs almost completely protected the encapsulated siRNA from RNase A digestion. Coupling of anti-human epidermal growth factor receptor (EGFR) Fab' to siRNA/SMLs enhanced EGFR-specific ...
Source: Biochimica et Biophysica Acta - February 28, 2018 Category: Biochemistry Authors: Mokhtarieh AA, Lee J, Kim S, Lee MK Tags: Biochim Biophys Acta Source Type: research
Preparation of siRNA encapsulated nanoliposomes suitable for siRNA delivery by simply discontinuous mixing
In this study, we prepared nanoliposomes encapsulating siRNA by simply discontinuous mixing of lipids in ethanol/ether/water mixture and acidic siRNA solution without use of special equipment. The simple mixing siRNA/liposomal particles (siRNA/SMLs) prepared using ethanol/ether/water (3:1:1) mixture showed 120.4 ± 20.2 nm particle size, 0.174 ± 0.033 polydispersity and 86.5 ± 2.76% siRNA encapsulation rate. In addition, the SMLs almost completely protected the encapsulated siRNA from RNase A digestion. Coupling of anti-human epidermal growth factor receptor (EGFR) Fab′ to siRNA/SMLs enhanced EGFR-specifi...
Source: Biochimica et Biophysica Acta (BBA) Biomembranes - March 6, 2018 Category: Biochemistry Source Type: research
Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
The objective of this work consists in formulating and optimizing the encapsulation of siRNA into lipid nanocapsules (LNCs) for efficient gene therapy on melanoma cells. SiRNA LNCs were prepared from DOTAP/DOPE lipoplexes, and the siRNA dose and lipid/siRNA charge ratio were assayed to improve the stability and encapsulation yield. Cryo-TEM imaging of the siRNA lipoplexes and LNC morphology revealed a specific organization of the siRNA DOTAP/DOPE lipoplexes as well as specific lipid microstructures. No cytotoxicity of the siRNA LNCs against the melanoma SK-Mel28 cell line was observed at concentrations of up to 500 ng/mL s...
Source: Biotechnology Journal - September 26, 2014 Category: Biotechnology Authors: Resnier P, LeQuinio P, Lautram N, André E, Gaillard C, Bastiat G, Benoit JP, Passirani C Tags: Biotechnol J Source Type: research
Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211041453. doi: 10.1177/15330338211041453.ABSTRACTDelivery of small-interfering RNA (siRNA) has been of great interest in the past decade for effective gene silencing. To overcome synthetic and regulatory challenges posed by nanoparticle-mediated siRNA delivery, antibody-siRNA conjugate (ARC) platform is emerging as a potential siRNA delivery system suitable for clinical translation. Herein, we have developed a delivery technology based on the ARC platform for stable delivery of siRNA called as Gelatin-Antibody Delivery System (GADS). In GADS, positively charged gelatin act...
Source: Cell Research - September 20, 2021 Category: Cytology Authors: K Sreedurgalakshmi R Srikar K Harikrishnan Lakshmi Srinivasan Reena Rajkumari Source Type: research
Formulation of glutathione responsive anti-proliferative nanoparticles from thiolated Akt1 siRNA and disulfide-crosslinked PEI for efficient anti-cancer gene therapy
In this study, thiol-modified siRNA (SH-siRNA) was delivered by bioreducible polyethylenimine (ssPEI), to enhance physicochemical properties of polyplexes and function of siRNA through disulfide bonding between SH-siRNA and ssPEI. The ssPEI was utilized to deliver Akt1 SH-siRNA for suppression of Akt1 mRNA and blockage of Akt1 protein translation, resulting in reduced cellular proliferation and the induction of apoptosis. Disulfide bondings between the ssPEI and SH-siRNA through thiol groups in both were confirmed by DTT treatment. Complexation between ssPEI and Akt1SH-siRNA was enhanced and reduced surface charge of ssPEI...
Source: Colloids and Surfaces B: Biointerfaces - January 9, 2015 Category: Biochemistry Source Type: research
Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy
Life Sci. 2022 Mar 5:120463. doi: 10.1016/j.lfs.2022.120463. Online ahead of print.ABSTRACTGene therapy can be used as a cancer therapy by affecting signaling networks participating in the aggressive behavior of tumors. Small interfering RNA (siRNA) is a genetic tool employed for gene silencing. The siRNA molecules have a length of 21-22 nucleotides, and are synthetic, short non-coding RNAs. The siRNA molecule should be loaded into the RISC complex to carry out its function to degrade mRNA and reduce protein expression. By targeting oncogenic pathways, siRNA can also promote chemosensitivity and reduce resistance. Doxorubi...
Source: Cancer Control - March 8, 2022 Category: Cancer & Oncology Authors: Mahshid Deldar Abad Paskeh Hamidreza Saebfar Mahmood Khaksary Mahabady Sima Orouei Kiavash Hushmandi Maliheh Entezari Mehrdad Hashemi Amir Reza Aref Michael R Hamblin Hui Li Ang Alan Prem Kumar Ali Zarrabi Saeed Samarghandian Source Type: research
Clinical pharmacology of siRNA therapeutics: current status and future prospects
Expert Rev Clin Pharmacol. 2022 Oct 17. doi: 10.1080/17512433.2022.2136166. Online ahead of print.ABSTRACTINTRODUCTION: Small interfering RNA (siRNA) has emerged as a powerful tool for post-transcriptional downregulation of multiple genes for various therapies. Naked siRNA molecules are surrounded by several barriers that tackle their optimum delivery to target tissues such as limited cellular uptake, short circulation time, degradation by endonucleases, glomerular filtration, and capturing by the reticuloendothelial system (RES).AREAS COVERED: This review provides insights into studies that investigate various siRNA-based...
Source: Expert Review of Clinical Pharmacology - October 17, 2022 Category: Drugs & Pharmacology Authors: Ahmed Khaled Abosalha Jacqueline Boyajian Waqar Ahmad Paromita Islam Merry Ghebretatios Sabrina Schaly Rahul Thareja Karan Arora Satya Prakash Source Type: research
